CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-06-12 | SCHENK LYNN Director | Grant or award | +880 | 7,909 | ||
| 2018-06-12 | SHERWIN STEPHEN A Director | Grant or award | +880 | 6,014 | ||
| 2018-06-01 | Ehlers Michael D EVP, Research and Development | Shares withheld for taxes | −460 | $297.09 | $137K | 4,513.17 |
| 2018-06-01 | Ehlers Michael D EVP, Research and Development | Option exercise | +1,384 | 5,897.17 | ||
| 2018-06-01 | Ehlers Michael D EVP, Research and Development | Shares withheld for taxes | −616 | $297.09 | $183K | 5,281.17 |
| 2018-06-01 | Ehlers Michael D EVP, Research and Development | Option exercise · Restricted Stock Unit | −1,384 | 3,612 | ||
| 2018-06-01 | Ehlers Michael D EVP, Research and Development | Other disposition · Restricted Stock Unit | −1,110 | 2,502 | ||
| 2018-05-02 | Vounatsos Michel Chief Executive Officer | Option exercise | +1,687 | 10,118.27 | ||
| 2018-05-02 | Vounatsos Michel Chief Executive Officer | Shares withheld for taxes | −750 | $274.13 | $206K | 9,368.27 |
| 2018-05-02 | Vounatsos Michel Chief Executive Officer | Option exercise · Restricted Stock Unit | −1,687 | 4,809 | ||
| 2018-05-02 | Vounatsos Michel Chief Executive Officer | Other disposition · Restricted Stock Unit | −1,557 | 3,252 | ||
| 2018-04-25 | DENNER ALEXANDER J Director | Purchase | +48,000 | $269.91 | $13.0M | 461,858 |
| 2018-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −405 | $282.35 | $114K | 4,006.82 |
| 2018-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise | +532 | 4,538.82 | ||
| 2018-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −237 | $282.35 | $67K | 4,301.82 |
| 2018-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise · Restricted Stock Unit | −532 | 1,160 | ||
| 2018-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Other disposition · Restricted Stock Unit | −312 | 848 | ||
| 2018-03-01 | COVINO GREGORY F VP, Chief Accounting Officer | Grant or award · Restricted Stock Unit | +531 | 531 | ||
| 2018-02-27 | Sandrock Alfred EVP, Chief Medical Officer | Sale | −259 | $290.83 | $75K | 6,553.38 |
| 2018-02-23 | Sandrock Alfred EVP, Chief Medical Officer | Sale | −908 | $293.44 | $266K | 6,553.38 |
Page 56 of 61 · 1,204 trades